Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Diseases | 3 | 2019 | 68 | 0.610 |
Why?
|
Kidney Neoplasms | 3 | 2015 | 74 | 0.540 |
Why?
|
Podocytes | 4 | 2023 | 38 | 0.530 |
Why?
|
Carcinoma, Renal Cell | 2 | 2015 | 44 | 0.450 |
Why?
|
Biopsy, Fine-Needle | 7 | 2013 | 59 | 0.430 |
Why?
|
Glomerulonephritis, IGA | 1 | 2011 | 7 | 0.380 |
Why?
|
Carcinoma, Papillary | 1 | 2010 | 20 | 0.350 |
Why?
|
Lymphatic Metastasis | 3 | 2010 | 86 | 0.350 |
Why?
|
Tumor Virus Infections | 1 | 2009 | 15 | 0.330 |
Why?
|
Polyomavirus Infections | 1 | 2009 | 23 | 0.320 |
Why?
|
Carcinosarcoma | 1 | 2006 | 2 | 0.270 |
Why?
|
Uterine Neoplasms | 1 | 2006 | 7 | 0.270 |
Why?
|
Adenoma | 2 | 2021 | 56 | 0.270 |
Why?
|
Pleural Neoplasms | 1 | 2006 | 11 | 0.250 |
Why?
|
Mesothelioma | 1 | 2006 | 14 | 0.250 |
Why?
|
Liver Neoplasms | 2 | 2011 | 90 | 0.250 |
Why?
|
Enterocolitis | 1 | 2005 | 4 | 0.250 |
Why?
|
Candidiasis | 1 | 2005 | 17 | 0.250 |
Why?
|
Carcinoma, Lobular | 1 | 2005 | 20 | 0.250 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2005 | 31 | 0.250 |
Why?
|
Immunocompromised Host | 1 | 2005 | 41 | 0.250 |
Why?
|
Humans | 23 | 2023 | 25165 | 0.240 |
Why?
|
Cerebral Hemorrhage | 1 | 2005 | 88 | 0.230 |
Why?
|
Colonoscopy | 2 | 2021 | 65 | 0.230 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 2 | 2023 | 15 | 0.210 |
Why?
|
Breast Neoplasms | 2 | 2015 | 379 | 0.210 |
Why?
|
Proteinuria | 2 | 2023 | 48 | 0.210 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2015 | 39 | 0.200 |
Why?
|
Coloring Agents | 1 | 2021 | 14 | 0.190 |
Why?
|
Mice | 6 | 2023 | 1300 | 0.180 |
Why?
|
Antibodies | 1 | 2021 | 45 | 0.180 |
Why?
|
Female | 12 | 2019 | 14161 | 0.180 |
Why?
|
Paraproteinemias | 1 | 2019 | 2 | 0.160 |
Why?
|
Inducible T-Cell Co-Stimulator Ligand | 1 | 2019 | 6 | 0.160 |
Why?
|
Integrin alphaVbeta3 | 1 | 2019 | 15 | 0.160 |
Why?
|
Middle Aged | 9 | 2015 | 8303 | 0.160 |
Why?
|
Adult | 5 | 2015 | 7259 | 0.150 |
Why?
|
Animals | 6 | 2023 | 3430 | 0.140 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 111 | 0.140 |
Why?
|
CD11b Antigen | 1 | 2017 | 14 | 0.140 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 14 | 0.140 |
Why?
|
Receptor, ErbB-4 | 1 | 2016 | 2 | 0.140 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 4 | 0.140 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2016 | 17 | 0.140 |
Why?
|
Diabetic Nephropathies | 1 | 2016 | 16 | 0.140 |
Why?
|
Macrophages | 1 | 2017 | 87 | 0.130 |
Why?
|
MicroRNAs | 1 | 2016 | 41 | 0.130 |
Why?
|
Receptor, ErbB-2 | 2 | 2006 | 44 | 0.130 |
Why?
|
Up-Regulation | 1 | 2016 | 162 | 0.130 |
Why?
|
Granulomatous Mastitis | 1 | 2015 | 3 | 0.120 |
Why?
|
Angiomyolipoma | 1 | 2015 | 3 | 0.120 |
Why?
|
Biopsy | 3 | 2021 | 181 | 0.120 |
Why?
|
Retrospective Studies | 5 | 2019 | 3185 | 0.110 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2017 | 174 | 0.110 |
Why?
|
Male | 7 | 2017 | 13815 | 0.110 |
Why?
|
Lung Neoplasms | 3 | 2011 | 544 | 0.110 |
Why?
|
Wilms Tumor | 1 | 2013 | 10 | 0.100 |
Why?
|
Bone Neoplasms | 2 | 2011 | 112 | 0.090 |
Why?
|
Urologic Neoplasms | 1 | 2011 | 4 | 0.090 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2011 | 17 | 0.090 |
Why?
|
Rhabdomyosarcoma | 1 | 2010 | 6 | 0.090 |
Why?
|
Trisomy | 1 | 2010 | 3 | 0.090 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2010 | 7 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 23 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 32 | 0.090 |
Why?
|
Soft Tissue Neoplasms | 1 | 2010 | 22 | 0.090 |
Why?
|
Cytodiagnosis | 2 | 2010 | 18 | 0.090 |
Why?
|
Nephrectomy | 1 | 2010 | 37 | 0.090 |
Why?
|
Disease-Free Survival | 1 | 2010 | 142 | 0.080 |
Why?
|
BK Virus | 1 | 2009 | 11 | 0.080 |
Why?
|
Adenocarcinoma | 1 | 2011 | 134 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 171 | 0.080 |
Why?
|
Fatal Outcome | 2 | 2006 | 48 | 0.080 |
Why?
|
Biomarkers, Tumor | 1 | 2010 | 184 | 0.080 |
Why?
|
Chondroma | 1 | 2008 | 6 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2009 | 105 | 0.070 |
Why?
|
Chondrocytes | 1 | 2008 | 130 | 0.070 |
Why?
|
Tissue Array Analysis | 1 | 2006 | 3 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2006 | 5 | 0.070 |
Why?
|
Mice, Knockout | 2 | 2019 | 278 | 0.070 |
Why?
|
Reed-Sternberg Cells | 1 | 2006 | 2 | 0.070 |
Why?
|
Cyclooxygenase 2 | 1 | 2006 | 28 | 0.070 |
Why?
|
Bronchi | 1 | 2006 | 12 | 0.070 |
Why?
|
Carcinoma, Large Cell | 1 | 2006 | 12 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2006 | 15 | 0.070 |
Why?
|
ErbB Receptors | 1 | 2006 | 50 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2006 | 67 | 0.070 |
Why?
|
Arteriovenous Malformations | 1 | 2006 | 3 | 0.060 |
Why?
|
Gastric Mucosa | 1 | 2006 | 9 | 0.060 |
Why?
|
Stomach | 1 | 2006 | 13 | 0.060 |
Why?
|
Arteries | 1 | 2006 | 13 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2006 | 19 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2006 | 342 | 0.060 |
Why?
|
Receptors, Progesterone | 1 | 2005 | 22 | 0.060 |
Why?
|
Cadherins | 1 | 2005 | 32 | 0.060 |
Why?
|
Signal Transduction | 2 | 2019 | 401 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2006 | 331 | 0.060 |
Why?
|
Receptors, Estrogen | 1 | 2005 | 54 | 0.060 |
Why?
|
Aged | 4 | 2015 | 8448 | 0.060 |
Why?
|
Integrins | 1 | 2023 | 13 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2015 | 4508 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2005 | 637 | 0.050 |
Why?
|
Treatment Outcome | 1 | 2010 | 3204 | 0.050 |
Why?
|
Staining and Labeling | 1 | 2021 | 14 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 1 | 2021 | 54 | 0.050 |
Why?
|
Observer Variation | 1 | 2021 | 89 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 318 | 0.040 |
Why?
|
Receptor, PAR-2 | 1 | 2019 | 2 | 0.040 |
Why?
|
Protein Domains | 1 | 2019 | 6 | 0.040 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 1 | 0.040 |
Why?
|
Protein Multimerization | 1 | 2019 | 15 | 0.040 |
Why?
|
Amino Acid Motifs | 1 | 2019 | 15 | 0.040 |
Why?
|
Adipocytes | 1 | 2019 | 18 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 14 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2019 | 43 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2019 | 62 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2019 | 13 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2019 | 15 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 38 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2019 | 63 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 96 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2021 | 641 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2019 | 209 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 273 | 0.040 |
Why?
|
Disease Management | 1 | 2019 | 89 | 0.040 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2017 | 2 | 0.030 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2017 | 2 | 0.030 |
Why?
|
Forkhead Box Protein O3 | 1 | 2017 | 5 | 0.030 |
Why?
|
Interferon Regulatory Factor-7 | 1 | 2017 | 4 | 0.030 |
Why?
|
Interferon Type I | 1 | 2017 | 9 | 0.030 |
Why?
|
Ribonucleases | 1 | 2016 | 8 | 0.030 |
Why?
|
Erlotinib Hydrochloride | 1 | 2016 | 11 | 0.030 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2016 | 19 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2016 | 18 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 49 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2019 | 567 | 0.030 |
Why?
|
Biomarkers | 1 | 2019 | 520 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 266 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2019 | 836 | 0.030 |
Why?
|
Ultrasonography, Mammary | 1 | 2015 | 10 | 0.030 |
Why?
|
Tuberous Sclerosis | 1 | 2015 | 12 | 0.030 |
Why?
|
Mammography | 1 | 2015 | 46 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 704 | 0.020 |
Why?
|
Radiography | 1 | 2013 | 566 | 0.020 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2011 | 10 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 2179 | 0.020 |
Why?
|
Chondroblastoma | 1 | 2008 | 2 | 0.020 |
Why?
|
Histocytological Preparation Techniques | 1 | 2008 | 3 | 0.020 |
Why?
|
Fibroma | 1 | 2008 | 4 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 2008 | 41 | 0.020 |
Why?
|
Adolescent | 1 | 2006 | 2018 | 0.010 |
Why?
|